Fear of places and situations that might cause panic, helplessness, or embarrassment.
Agoraphobia is an anxiety disorder that often develops after one or more panic attacks.
Symptoms include fear and avoidance of places and situations that might cause feelings of panic, entrapment, helplessness, or embarrassment.
Treatments include talk therapy and medication.
Cluster Number: F-1
Wiki Number: W003
US Patients: 1.7% Adults
Sex Ratio: M-2W
Age Onset: 20+
Brain Area: Extra epinephrine – poor balance
Symptoms: environment unsafe-no escape
Progression: Open spaces or outside home; may lead to 10-30 minute panic attack or PTSD
Medications: antidepressants; anti-anxiety
Therapies: relaxation, systematic desensitization, expanding exposuresCBT-50%
DRUG DISCOUNT PROGRAMS WHICH MAY BE AVAILABLE.
(This may not be a complete lists of companies offering drug discounts.)
1. GoodRx.com-On their website type in the name of the drug for coupons and get prices from pharmacy chain-stores. Discounts can range up to 80% and their card will be honored in 70,000 pharmacies.
2. Optum Perks Discount Card-Their website allows registration for their cards for those age 13 and older. “Tools and information may very based on your plan benefits.”
3. RxSaver-com. Their website claims up to 80% savings and accepted at thousands of pharmacies with five pharmacy chains shown. Their program prints coupons on demand.
4. WellRx-Print their card from their website and then save up to 80% at pharmacy counters on 1167 drug choices. Their ad shows 20 pharmacy store-chains.
YOUTUBE VIDEOS BY DIAGNOSIS:
(Additional videos may also appear in YouTube.)
AMAZON’S BOOK TITLES BY DIAGNOSIS:
(Additional titles may also appear in Amazon.)
(Your Library may have this book, or find it through InterLibrary-Loan.)
The Agoraphobia Workbook
THIS DIAGNOSIS MAY QUALIFY FOR SCHOOL SPECIAL PROGRAM.
THIS DIAGNOSIS MAY QUALIFY FOR SOCIAL SECURITY DISABILITY BENEFITS.
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Psychosocial treatment for panic disorder: An umbrella review of systematic reviews and meta-analysesby Ana Rabasco on January 22, 2022
CONCLUSIONS: Future reviews should focus on improving their methodological quality. Although the included reviews supported CBT as an efficacious treatment for reducing panic symptoms among adults, future research could focus on how CBT compares to other psychosocial treatments and the efficacy of CBT for PD among other populations (e.g., children and adolescents) and among diverse cultural groups.
- COVID-19 vaccine hesitancy in patients with mental illness: strategies to overcome barriers-a reviewby Ebrahim Payberah on January 21, 2022
CONCLUSION: Existing literature on the rates of vaccine hesitancy among people with mental health illness is limited. The mental health illness may increase the risk of hesitancy especially in patients having certain emotional disorders such as anxiety and phobia. More studies addressing vaccine hesitancy rates and factors associated with the mentally ill population need to be done in the future.
- Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trialsby Natasha Chawla on January 20, 2022
CONCLUSION: The findings suggest that SSRIs provide high rates of remission with low risk of adverse events for the treatment of panic disorder. Among SSRIs, sertraline and escitalopram were associated with high remission and low risk of adverse events. The findings were, however, based on studies of moderate to very low certainty levels of evidence, mostly as a result of within study bias, inconsistency, and imprecision of the findings reported.
- Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trialsby Davide Papola on January 20, 2022
CONCLUSIONS: CBT and short-term psychodynamic therapy are reasonable first-line choices. Studies with high risk of bias tend to inflate the overall efficacy of treatments. Results from this systematic review and network meta-analysis should inform clinicians and guidelines.